Autopsy report · NCT04870164

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

“Due to hypersensitivity observed in 3 subjects, although no stopping rules were met, the Sponsor decided to halt recruitment for further investigation. After analysis of PK, i.m. administration was not required, and recruitment stopped.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 1 year 2 months before it stopped.
• 53 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Molecular Partners AG

Sponsor type

Industry

Conditions

COVID-19

Interventions

Ensovibep; Placebo

Participants

53

Sites

1

Countries

United Kingdom

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.